Sodium Orthovanadate is a potent alkaline phosphate inhibitor.
Sodium Orthovanadate is used in the diabetes study. Sodium orthovandate was used to prepare the stop solution in dephosphorylation assay of insulin receptor kinase. It was one of the reagents used in the development of Matrix ChIP that utilizes surface-immobilized antibodies.
Inhibits ATPase, alkaline phosphatase and tyrosine phosphatase. Decavanadate, which is formed at acidic pH, inhibits inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release from endocrine cells and blocks IP3 binding to its receptor in brain tissue.
Sodium orthovandate suppresses the activation of p53-mediated apoptosis triggered in response to radiation. It reduces the detrimental effects of hematopoietic syndrome, hematopoiesis and delayed genotoxic effects of induced by total body irradiation of mice. In combination with menadione, orthovandate prevents the migration of detached human glioma cells in response to anti-cancer drugs.
Purity: ≥96%
Key Applications: Alkaline phosphate inhibitor
Application Areas: Molecular biology
Product Type: Biochemicals
Boiling Point: 3,380°C(Lit.)
Melting Point: 850-866°C(lit.)
Presentation: White Powder
Format: Powder
Solubility: Soluble in water (50 mg/mL- clear to hazy, colorless to faint yellow solution).
Storage & Handling: Store at Room Temperature (15-30°C.)